key: cord-0870233-x3okaio7
authors: Jarisch, Andrea; Wiercinska, Eliza; Huenecke, Sabine; Bremm, Melanie; Cappel, Claudia; Hauler, Julian; Rettinger, Eva; Soerensen, Jan; Hellstern, Helen; Klusmann, Jan-Henning; Ciesek, Sandra; Bonig, Halvard; Bader, Peter
title: Immune responses to SARS-CoV-2 vaccination in young patients with anti-CD19 CAR-T-induced B-cell aplasia
date: 2022-04-26
journal: Transplant Cell Ther
DOI: 10.1016/j.jtct.2022.04.017
sha: d1a493874021e51c734f72c5e734ae498e968555
doc_id: 870233
cord_uid: x3okaio7

Background: SARS-CoV-2 vaccines are capable of inducing combined humoral and cellular immunity. Which is more relevant for their potent protective effects is unclear, but isolated T-cell responses without seroconversion in healthy household members of COVID-patients suggest that T-cell responses effectively protect against clinical infection. Oncological patients have an outsize risk of unfavorable outcomes after SARS-CoV-2 infection and therefore were prioritized when vaccines first became available, although the quality of their immune response to vaccination was expected to be sub-optimal, as subsequent studies have confirmed. Inherently, patients with anti-CD19 CAR-T-mediated B-cell aplasia would be incapable of generating humoral responses, so that assessment of the vaccine-induced cellular immunity was all the more important to gauge whether the vaccine can induce meaningful protection. A salient difference between T-cell and humoral responses is the former's relative impassiveness to mutations of the antigen, as is more relevant than ever since the advent of the omicron variant. Objective: The objective of this study was to assess in a cohort of juvenile CD19 CAR-T patients with enduring B-cell aplasia, the immune cell composition and spike protein-specific T-cell responses before and after the first and second doses of SARS-CoV-2 mRNA vaccine. Study design: The prospective study included all patients aged >12 years diagnosed with multiply relapsed B-cell precursor acute lymphoblastic leukaemia (ALL) and treated with anti-CD19 chimeric antigen receptor T-cell (CAR-T19) therapy in our center. The primary endpoint was the detection of cell-mediated and humoral response to vaccine (flow cytometry and anti-S immunoglobulin G, respectively). Secondary endpoints included the incidence of vaccine-related grade 3 or 4 adverse events, GvHD exacerbation, relapse and the influence of the vaccine on CAR-T cells and lymphocyte subset. Results: Even though half of the patients exhibited sub-normal lymphocyte counts and marginal CD4/CD8 ratios, after two vaccinations all showed brisk T-cell responsiveness to spike protein, predominantly in the CD4 compartment, which was quantitatively well within the range of healthy controls. No severe vaccine-related grade 3 or 4 adverse events, GvHD exacerbation or relapse was observed in our cohort. Conclusion: We posit that SARS-CoV-2 mRNA vaccines induce meaningful cellular immunity in patients with isolated B-cell deficiency due to anti-CD19 CAR-T therapy.

COVID-19 disease is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); its course can be severe, the overall mortality approaching one percent among unvaccinated adults (1) . Patients with malignant diseases and an impaired immune system, especially patients after hematopoietic stem cell transplantation (HSCT), and immune cell therapy, have an increased risk of an aggravated course of the disease or death (2) (3) (4) and despite the expectation of less than optimal vaccine responsiveness were granted prioritized access.

In December 2020/January 2021, first the US Food and Drug Administration (FDA) and then the European Medicines Agency (EMA) approved the BNT162b2 mRNA COVID-19 (Pfizer-BioNTech; Pfizer, New York, NY) vaccine for the prevention of COVID-19, based on a phase III study that showed 94.6% clinical efficacy in the general population (5) . Humoral responses after one dose are low, whereas the second dose strongly enhances the serological response. It is thus recommended that hematology-oncology and HSCT patients should receive their vaccinations 3-4 weeks apart (6) . More recently, in May 2021, the EMA also approved BNT162b2 for children 12-15 years old; it is important to note that prior to that date, adolescent hematology-oncology patients did not have access to SARS-CoV-2 vaccines. The SARS-CoV-2 vaccine for children with a reduced dose aged 5 to 11 years was released and approved in December 2021.

The effectiveness of SARS-CoV-2 vaccination in patients with hematologic malignancies appears to be influenced by the therapy and the underlying disease.

Several studies have shown blunted immune responses to the mRNA vaccines in patients with solid organ transplant (7) as well as in patients with multiple myeloma, CLL, lymphoma, myeloproliferative malignancies and after HSCT compared to healthy individuals (8) (9) (10) (11) (12) . Unsurprisingly, especially poor serologic responses were seen in B-lineage NHL treated with depleting anti-CD20 antibodies within 12 months prior to vaccination (11) .

Although the FDA, European Society for Blood and Marrow Transplantation (EBMT), American Society of Transplantation and Cellular Therapy (ASTCT), American Society of Hematology (ASH) and National Marrow Donor Program (NMDP) recommend SARS-CoV-2 vaccination for immunosuppressed patients (13) (14) (15) , limited data are available on its efficacy and safety in patients undergoing chimeric antigen receptor (CAR) immune effector cell therapy.

CD19-targeting CAR T-cell-therapy (CAR-T19) is a relevant treatment option for patients with refractory and recurrent lymphoid malignancies, especially acute lymphoblastic leukemia (ALL) and diffuse large B-cell lymphoma (DLBCL). Due to absolute B-cell aplasia after successful CAR-T19 cell therapy, a humoral immune response is not expected after vaccination. There are limited data about the cellular response rate of CAR-T19 patients after SARS-CoV-2 vaccination. Two small series with adult patients reported response rates of 0 and 36% (16) (17) . Similar data for children/adolescents after anti-CD19-CAR-T cell therapy are not available.

All approved vaccines induce a combined humoral and cellular immune response in the majority of healthy recipients, whereas in cancer patients typically both are blunted, at least at the cohort level. The benefit of the one over the other is therefore impossible to dissect. However, cocktails of recombinant neutralizing antibodies appear to provide clinically meaningful protection from progression to severe COVID-19. On the other hand, studies of household members of COVID-19 patients who neither got sick nor developed a humoral response showed robust SARS-CoV-2specific T-cell responses (18) . What emanates, therefore, is that both branches of the adaptive immune system by themselves provide some protection against COVID-19 disease. The question whether B-cell-deficient patients are able to mount specific T-cell immunity in response to SARS-CoV-2 vaccination is thus more than just academic.

In this study, we aimed to evaluate the safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine in young patients who had previously received anti-CD19 CAR Tcell therapy and remained B-cell aplastic.

The prospective study included eight patients aged >12 years (and hence, eligible for SARS-CoV-2 vaccination) diagnosed with multiply relapsed B-cell precursor acute In personal or telephone contact, we asked the patients about vaccine-related side effects (pain at the injection site, headache, fever, allergy, arthralgia, weakness) or GvHD exacerbation. We graded acute and chronic GvHD according to EBMT-NIH-CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease (19) .

The primary endpoint was the detection of cell-mediated and humoral response to vaccine (flow cytometry and anti-S immunoglobulin G, respectively).

Secondary endpoints included the incidence of vaccine-related grade 3 or 4 adverse events, GvHD exacerbation, relapse and the influence of the vaccine on CAR-T cells and lymphocyte subset.

We examined frequency and concentration of lymphocytes, CD3+ T-cells, CD3+ p<0.002). Slightly, but not significantly higher readings were also obtained for IFN-y+ CD4+ T-cells. SARS-CoV-2-specific T-helper cell concentrations ranged between 0.5-12 /µL. A vaccine response was also seen for in all patients for T8 cells (Fig. 4C) , albeit relatively weaker than in the T4 compartment. Compared to healthy similarly vaccinated controls, the frequency of S-protein-reactive T4 cells was even higher ( figure 4E ). For TNF-α, CD40L and IL-2+CD40L-producing T-helper cytokines, the comparison between CAR-T patients and healthy volunteers was highly significant with p<0.001. For IL-2 alone, there was p <0.01. For IFN-γ alone and INF-γ+TNF-α co-producing T4, there was no statistical significance ( figure 4E ).

The immune response appears to be a multi-cytokine producing population (suppl. figure 1 ). These polyfunctional T cells form the major part and primarily produce CD40L, IL-2 and CD154 (suppl. figure 1B) . The IFN-γ producing population is a much smaller and independent population.

All 8 patients maintained regular social contacts, including attending work or school.

Three contracted SARS-CoV-2; although the viruses were not sequenced, the timing of the infection suggests one Delta and two Omicron infections. Two had mild symptoms (rhinitis and mild fever), one patient's infection was caught during routine screening during an outpatient department visit. Out of an abundance of caution, the latter patient received sotrovimab one day after the positive PCR result and he remained asymptomatic throughout. were quite safe and tolerable in our cohort.

In spite of the observed robust cellular immunity to spike protein, the patients were advised to continue to be cautious. As to the protective value of isolated T-cell responses one can, therefore, only speculate. According to earlier reports, some household member of COVID19 patients who remained SARS-CoV-2 PCR as well as anti-SARS-CoV-2 antibody negative during quarantine were later found to have mounted isolated SARS-CoV-2 specific T-cell responses (18) . The authors proposed that these were at least somewhat protective as they had prevented development of clinical COVID-19. We therefore posit that likely vaccinated CAR-T19 vaccines, but remained moot on the (clinical) value of immunization in this patient cohort (15, 23) .Our response rate of 100% is much higher than in the only other report on vaccine-induced T-cell immunity in CAR-T19 patients (17) . Even though slightly different technology was used for SARS-CoV-2-specific T-cell detection, in this adult cohort the response rate was only 50% (six/12). We propose that the twofold higher response rate in our patient cohort is due to their young age (24, 25) .

Like the SARS-CoV-2 vaccine, most other vaccines with the exception of polysaccharide vaccines also induce adaptive T-cell responses. On the basis of the evidence provided here, we therefore propose to reconsider attitudes to vaccination of CAR-T19 patients with non-live vaccines (26) . It will be important to supplement these with investigation of antigen-specific T-cell responses (15) .

In summary, we demonstrate robust, and potentially clinically meaningful, T-cell responses to SARS-CoV-2 vaccines in patients with CAR-T19-mediated humoral immunodeficiency. 

Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data

COVID-19 in transplant recipients. The Spanish experience

Risk factors and outcome of COVID-19 in patients with hematological malignancies

Evaluation of COVID-19 Mortality and Adverse Outcomes in US Patients With or Without Cancer

Safety and Efficacy of the BNT162b2 mRNA Covid-19

Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer. Interim analysis of a prospective observational study

Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients

Severe impairment of T-cell responses to BNT162b2 immunization in multiple myeloma patients

Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies

Anti-SARS-CoV-2 antibody response in patients with chronic lymphocytic leukemia

Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma

SARS-CoV-2 specific T-cells are generated in less than half of allogeneic HSCT recipients failing to seroconvert after COVID-19 vaccination

ASH-ASTCT COVID-19 Vaccination for HCT and CAR T Cell Recipients: Frequently Asked Questions

Management of adults and children receiving CAR Tcell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)

Response to SARS-CoV-2 vaccination in patients after hematopoietic cell transplantation and CAR T-cell therapy

Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Patients after Allogeneic HCT or CD19-based CART therapy-A Single-Center Prospective Cohort Study

Intrafamilial Exposure to SARS-CoV-2 Associated with Cellular Immune Response without Seroconversion

EBMT-NIH-CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessment

Immunophenotyping of blood lymphocytes in childhood. Reference values for lymphocyte subpopulations

Percentiles of Lymphocyte Subsets in Preterm Infants According to Gestational Age Compared to Children and Adolescents

Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study

Management of adults and children undergoing chimeric antigen receptor T-cell therapy. Best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)

T cell reconstitution after bone marrow transplantation into adult patients does not resemble T cell development in early life

Age-matched lymphocyte subpopulation reference values in childhood and adolescence. Application of exponential regression analysis

A guide to vaccinology. From basic principles to new developments